Ultragenyx Pharmaceutical Inc. (RARE)
|52 Week Range||33.36-85.53|
|1y Target Est||-|
|DCF Unlevered||RARE DCF ->|
|DCF Levered||RARE LDCF ->|
|Debt / Equity||338.43%||Strong Buy|
Upgrades & Downgrades
Latest RARE news
7 Biotech Stocks to Buy for Breakthrough Treatments and Cures
29 March 2023
While it's a common conspiracy theory – and comedic punchline – that medical innovators only seek to manage problems rather than cure them, the reality is that several biotech stocks to buy undergird ...
Ultragenyx to Present at Guggenheim's Genomic Medicines and Rare Disease Days
28 March 2023
NOVATO, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for se...
Ultragenyx (RARE) Q4 Earnings Miss, Revenues Increase Y/Y
17 February 2023
Ultragenyx (RARE) reports a wider loss in the fourth quarter while revenues increase on growth in demand for its drugs.
Ultragenyx Pharmaceutical Inc. (RARE) Q4 2022 Earnings Call Transcript
16 February 2023
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE ) Q4 2022 Earnings Conference Call February 16, 2023 5:00 PM ET Company Participants Joshua Higa - Head of Investor Relations Emil Kakkis - Founder, Preside...
Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates
16 February 2023
Ultragenyx (RARE) delivered earnings and revenue surprises of -6.40% and 0.27%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Ultragenyx: Rating Speculative Buy, Playing Setrusumab Data Release
10 February 2023
Ultragenyx has been punished on the chart over the past 2 years to date. Investors haven't rewarded the company's top-line growth, nor recognized the potential in its investigational pathways.
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2022 Financial Results and Corpo...
9 February 2023
NOVATO, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for seri...
Ultragenyx (RARE) Posts Preliminary '22 Results, Gives '23 View
9 January 2023
Ultragenyx (RARE) reports preliminary product revenues for its marketed drugs, Crysvita, Mepsevii and Dojolvi for the full year 2022. The company issues product revenue guidance for 2023.
Ultragenyx to Present at the 41st Annual J.P. Morgan Healthcare Conference
4 January 2023
NOVATO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser...
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
Stock Value >
Financial Summary > Financial Statements > Financial Quarter Statements > Ratios Analysis > Dupont Analysis > Free Cash Flow > Operating Data > Balance Sheet Data >